We serve Chemical Name:methyl carbonate,tributyl(methyl)azanium CAS:274257-37-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:methyl carbonate,tributyl(methyl)azanium
CAS.NO:274257-37-3
Synonyms:Tributylmethylammonium methyl carbonate;Methyltributylammonium methyl carbonate;Tributylmethylammonium methyl carbonate solution
Molecular Formula:C15H33NO3
Molecular Weight:275.42700
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:n20/D 1.408
PSA:49.36000
Exact Mass:275.24600
LogP:2.80940
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 1987 3/PG 3
Packing Group:
Contact us for information like Tributylmethylammonium methyl carbonate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Tributylmethylammonium methyl carbonate solution physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Tributylmethylammonium methyl carbonate Use and application,Methyltributylammonium methyl carbonate technical grade,usp/ep/jp grade.
Related News: Under the terms of the agreement, ICIG will purchase substantially all of the pharmaceutical intermediates business, excluding the drug delivery technologies portion of the business. methyl carbonate,tributyl(methyl)azanium manufacturer Cases recorded in Thailand, Taiwan, Germany, Vietnam, Japan, France and the United States involved patients who had not been to China. methyl carbonate,tributyl(methyl)azanium supplier The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy. methyl carbonate,tributyl(methyl)azanium vendor The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy. methyl carbonate,tributyl(methyl)azanium factory The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.
